A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of escalating doses of
mapatumumab in combination with sorafenib in subjects with advanced Hepatocellular Carcinoma
who are positive for hepatitis B surface antigen or hepatitis C antibody.